Under the terms of the agreement, Invitrogen and PamGene will co-market Invitrogen’s nuclear hormone receptor proteins and Lanthascreen assay technology with PamGene’s portfolio of microarray-based nuclear hormone receptor screening tools. This is expected to create a complete offering for compound screening in drug discovery in the areas of cancer, diabetes and heart disease.